Sirtex Medical Ltd Buy
|
|
- Britton Stephens
- 5 years ago
- Views:
Transcription
1 Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product SIR-Spheres. The recent share price depreciation offers investors an attractive risk/reward proposition at current valuation, in our view. The Company has spent approximately A$60m into five major clinical trials over the past five years, all which are now approaching their completion. The purpose of the studies is to determine the efficacy of SIR-Spheres as a first-line of treatment for liver cancer rather than being used as a salvage treatment (that is, used only after other preferred/standard treatments fail such as surgery/chemotherapy). Our view is the current valuation is ascribing little to no value to potentially positive data results from these studies. Given SRX is already a profitable company (>$200m in revenue and >A$50m in NPAT), the potential growth in SRX s existing revenue lines alone justifies current valuation. Hence, at these levels investors are essentially getting any upside from these data results as a free option, in our view. SRX is due to release the results of one of its clinical trials SARAH on 22 April in Amsterdam. SRX is trading on a 12-month forward blended PE-multiple of 15.5x, which is 44% below its six-year average, whilst offering an attractive growth profile. SRX s key product SRX-Spheres. SRX main product SIR-Spheres microspheres are used to deliver targeted internal radiation therapy directly to liver tumours via the hepatic artery, a short blood vessel that supply oxygenated blood to the liver. This therapy is referred to as Selective Internal Radiation Therapy (SIRT) and is performed using minimally invasive techniques by interventional radiologists. SIR-Spheres are tiny radioactive polymer spheres that emit cancer-killing radiation yet minimize damage to surrounding healthy tissue. SIR-Spheres microspheres are currently used in primary liver cancer (hepatocellular carcinoma) and secondary liver cancer (metastatic liver cancer). SIR-Spheres achieved FDA-approval in 2002 for the treatment of metastatic colorectal cancer (mcrc) a type of cancer which spreads to other parts of the body via blood after cancer cells break from a colorectal tumour (cancer of the colon or rectum). When does SRX treatment come in? Surgery to have the cancer removed is the only cure, however approximately 85% of mcrc patients are unable to have surgery. Therefore, they start chemotherapy (the standard treatment). Patients who do not respond to chemotherapy (that is the disease continues to advance), then seek salvage treatments (e.g. less proven treatments like SIRT / drugs in clinical trials etc). Clinical trial pipeline to expand addressable market. SRX is looking to expand the use of SIR-Spheres and over a five-year period has spent A$60m into 5 major post marketing randomized clinical trials, which are nearing completion. The studies are designed to demonstrate the efficacy of SIR-Spheres microspheres as a first-line treatment for liver cancer either in combination with, or against the current standard of care chemotherapy. If the Company can achieve this it would significantly increase its addressable market. SARAH. Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Sirtex s SIRveNIB (Asia Pacific) and SARAH (France) studies are multi-centre randomized controlled trials (RCT) using SIR-Spheres microspheres versus the approved drug sorafenib (Nexavar) in advanced HCC. On 22 April, SRX will report the results of the SARAH study in Amsterdam. A clinically meaningful improvement over sorafenib could be a positive catalyst for SRX share price as it would increase SRX s addressable market. Our valuation sees +26% upside to current share price. We have set out price target using three methodologies DCF (A$21.53), PE-multiple (A$20.29) and EV / EBITDA (A$19.71). For our DCF valuation we forecast cash flows out to 2021 and use a WACC of 9.5% (long-term growth rate of 2.5%, risk-free rate of 4% and equity risk premium of 5.5%). Our multiple valuations are based on the average of SRX s trading multiples and its key global competitor BTG Plc, listed on the London Stock Exchange.
2 Investment Thesis We rate SRX as a BUY for the following reasons: Attractive valuation relative to domestic and global peers post recent share price decline. Positive data results from SARAH (due on the 22 nd April 2017 in Amsterdam) and FOXFIRE. We believe SRX current share price is factoring in minimal value from future growth options (that is, positive outcomes from recent studies). Significant market opportunity, given an under-penetrated market. Proposed A$30m share buyback still come (expected in June 2017). Leverage to a falling AUD/USD. Key Risks We see the following key risks to our investment thesis: Adverse implications / results from clinical trial studies. Unable to grow treatment centre footprint. Limited to one key product at the moment. Competitive pressure - loss of market share in key markets. Improved or better alternative treatment. Execution risk. Value destructive acquisition. A stronger AUD / USD. Company Description Sirtex Medical (SRX) is a global life-sciences company that develops and delivers effective oncology treatments using novel small particle technology. The Company s current lead product is a targeted radiation therapy for liver cancer called SIR- Spheres Y-90 resin microspheres. The company has supplied over 73,000 doses to treat patients with liver cancer at 1,060 medical centres in over 40 countries. The Company has manufacturing and logistics operations in the US, Germany and Singapore.
3 Quick Company Primer SRX is a global healthcare company providing radiation therapy for liver cancer. Main product SIR-Spheres Y-90 resin microspheres. SRX s main product SIR- Spheres microspheres are used to deliver targeted internal radiation therapy directly to liver tumours via the hepatic artery, a short blood vessel that supply oxygenated blood to the liver. This therapy is referred to as Selective Internal Radiation Therapy (SIRT) and is performed using minimally invasive techniques by interventional radiologists. SIR-Spheres are tiny radioactive polymer spheres that emit cancerkilling radiation yet minimize damage to surrounding healthy tissue. SIR-Spheres microspheres are currently used in primary liver cancer (hepatocellular carcinoma) and secondary liver cancer (metastatic liver cancer), where the liver tumour has originated from cancer in another part of the body. SIR-Spheres achieved FDAapproval in 2002 for the treatment of metastatic colorectal cancer (mcrc) a type of cancer which spreads to other parts of the body via blood after cancer cells break from a colorectal tumour. When is it used? Surgery to have the cancer removed is the only cure, however approximately 85% of mcrc patients are unable to have surgery. Therefore, they start chemotherapy (the standard treatment). Patients who do not respond to chemotherapy (that is the disease continues to advance), then seek salvage treatments (e.g. less proven treatments like SIRT). Clinical trials pipeline. SRX is looking to expand the use of SIR-Spheres and over a five-year period has spent A$60m in 5 major post marketing randomized clinical trials, which are nearing completion. The studies are designed to demonstrate the efficacy of SIR-Spheres microspheres as a first-line treatment for liver cancer either in combination with, or against the current standard of care chemotherapy. If the Company can achieve this it would significantly increase its addressable market. Figure 1: SRX clinical trials Source: Company Metastatic colorectal cancer (mcrc). SRX reported the major findings of the SIRFLOX study at the ASCO Annual Meeting in Chicago in May Patients treated with SIR-Spheres microspheres saw an additional 7.9 months or 62.7% improvement in Progression-Free Survival (PFS) in their lives versus chemotherapy alone and a 31% reduction in the risk of progression, which was highly significant and clinically meaningful. SIR-Spheres microspheres tripled the complete response rate, where no evidence of disease in the liver could be detected, to 6% of all patients. Overall Survival (OS) data from SIRFLOX will be combined with OS data from the FOXFIRE and FOXFIRE Global studies, representing over 1,100 patients.
4 Hepatocellular carcinoma (HCC). HCC is the most common form of liver cancer and most commonly occurs in people with liver disease (especially people with chronic hepatitis B and C). Sirtex s SIRveNIB (Asia Pacific) and SARAH (France) studies are multi-centre randomized controlled trials using SIR-Spheres mircospheres versus the approved drug sorafenib (Nexavar) in locally advanced HCC. SORAMIC (pan European) is a multi-centre randomized controlled trial using SIR-Spheres microspheres in combination with sorafenib versus soranfenib alone. SRX impressive 5-yr growth profile. As at FY16 results, SRX dose sales (that is number of units sold) were 11,931, representing 5-year compound annual growth rate (CAGR) of +19.1%. Group revenue was A$232.5m in FY16, representing 26.9% CAGR over a 5-yr period. The Americas is SRX s largest market, making up 71% units sold and 80% of group revenue. The remaining component is made up of: Europe, Middle East, Africa (units sold 21%; revenue 18%) and Asia Pacific (units sold 8%; revenue 2%). SRX Relative Valuation PE-multiple valuation. Relative to its historical trading average SRX forward PEmultiple is trading at a 44% discount. Figure 2: SRX PE-multiple chart Current PE 15.5x versus average 27.6x 60.0x 50.0x 40.0x 30.0x 20.0x 10.0x 0.0x Apr-12 Apr-13 Apr-14 Apr-15 Apr-16 Apr-17 SRX 12-mth PE-Multiple (Blended) Average Source: BTIG, Bloomberg
5 Valuation versus global & domestic comparables. SRX is screening attractively versus key competitor BTG and Australian health care peers. While we understand comparing SRX to Australian health care listed companies is not apples for apples, the purpose is to highlight SRX attractiveness to investors seeking health care exposure in the Australian market. Figure 3: SRX relative versus global and domestic healthcare peers Current FWD PE Div Yield EV/EBITDA Price 1-YR 2-YR 1-YR 2-YR 1-YR 2-YR Global Comps SIRTEX MEDICAL LTD x 14.8x 1.6% 2.0% 12.7x 9.5x BTG PLC x 19.9x 0.0% 0.0% 18.4x 12.9x Average 24.2x 17.3x 0.8% 1.0% 15.6x 11.2x SRX versus Group Average -19.3% -14.7% -18.2% -15.2% Australian Healthcare Comps SIRTEX MEDICAL LTD x 14.8x 1.6% 2.0% 12.7x 9.5x ANSELL LTD x 15.8x 2.5% 2.6% 11.1x 10.2x COCHLEAR LTD x 32.1x 2.0% 2.2% 23.3x 20.8x CSL LTD x 26.4x 1.5% 1.7% 22.0x 19.0x HEALTHSCOPE LTD x 19.3x 3.3% 3.5% 12.7x 12.3x RAMSAY HEALTH CARE LTD x 23.9x 1.9% 2.2% 12.8x 11.8x PRIMARY HEALTH CARE LTD x 16.9x 3.3% 3.8% 8.1x 7.6x SONIC HEALTHCARE LTD x 18.0x 3.5% 3.9% 12.8x 11.6x RESMED INC-CDI x 22.3x 2.1% 2.3% 17.0x 15.1x FISHER & PAYKEL HEALTHCARE C x 27.2x 2.1% 2.5% 19.8x 16.9x VIRTUS HEALTH LTD x 13.5x 4.8% 5.2% 9.4x 8.5x MONASH IVF GROUP LTD x 14.6x 4.5% 4.7% 10.8x 10.0x Average 23.2x 20.4x 2.8% 3.0% 14.4x 12.8x SRX versus Group Average -15.9% -27.5% -41.9% -33.6% -11.4% -25.7% Source: BTIG, Bloomberg Figure 4: SRX Financial Summary
6 Year-end June ($ millions) PROFIT & LOSS (P&L) FY14A FY15A FY16A FY17E FY18E FY19E Revenue Operating Expenses EBITDA % Margin 23.8% 29.2% 31.2% 27.2% 30.2% 31.9% Depreciation & Amortisation EBIT % Margin 22.6% 27.8% 28.3% 24.9% 28.7% 30.6% NPAT Underlying NPAT Underlying EPS (cps) DPS (cps) Growth Rates: Revenue 36.1% 32.0% 4.5% 18.4% 8.5% EBIT 67.9% 34.4% -8.3% 36.7% 15.6% Underlying NPAT 69.0% 32.8% -10.5% 30.7% 14.7% VALUATION FY14A FY15A FY16A FY17E FY18E FY19E PE multiple (x) P/B ratio (x) Dividend Yield (%) EV/Sales (x) EV/EBIT (x) BALANCE SHEET SUMMARY FY11A FY12A FY13A FY14A FY15A FY16A Cash Current Receivables Current Inventories Property, Plant & Equipment Other Total Assets Current Payables Total Debt Other Liabilities Total Liabilities Shareholders Equity Net Debt / Equity -71.4% -67.2% -59.1% -48.8% -51.1% -55.3% Net Debt / (ND+E) % % % -95.3% % % CASH FLOW SUMMARY FY11A FY12A FY13A FY14A FY15A FY16A Net Income Depn & Amortisation Other Non-cash Adj Changes in Non-cash capital Operating Cash Flow Capital Expenditure Free Cash Flow Source: BTIG, Company, Bloomberg
7 Disclaimer This document is provided by Vested Equities Pty Ltd (ABN ; AFSL ) ( Vested ). The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor s objectives, financial situation and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Vested nor its associates make any recommendation or warranty concerning the accuracy, or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and Vested is not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate. Vested and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Vested does, and seeks to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities. Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Vested, its associates, officers, directors, employees and agents. Except for any liability which cannot be excluded, Vested, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Vested is not liable to recipients in any matters whatsoever otherwise recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Vested does not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document. The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Vested.
For personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationCombined FOXFIRE Study Data Presented at ASCO Annual Meeting
ASX/MEDIA RELEASE 6 th June 2017 Combined FOXFIRE Study Data Presented at ASCO Annual Meeting Sydney, Australia; 6 th June 2017 Sirtex Medical Limited (ASX:SRX) announces the oral abstract of the combined
More informationSirtex Medical Limited (ASX:SRX)
Sirtex Medical Limited (ASX:SRX) Macquarie Australia Conference Mr Gilman Wong, CEO Dr David Cade, CMO Sydney, 8 th May 2014 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd 1 Understanding
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationSIRveNIB Study Data Presented at ASCO Annual Meeting
ASX/MEDIA RELEASE 5 th June 2017 SIRveNIB Study Data Presented at ASCO Annual Meeting Sydney, Australia; 5 th June 2017 Sirtex Medical Limited (ASX:SRX) announces the oral abstract of the SIRveNIB clinical
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationCorcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationFor personal use only
ASX / MEDIA RELEASE 1 st June 2015 ASCO Peer Review Supports the Benefits of SIR-Spheres Y-90 Resin Microspheres in the Liver SIRFLOX results confirmed as both statistically significant and clinically
More informationWntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in
More informationOncosil Medical (OSL) BUY: Cash and clinical data behind them now. Key points. Risks and catalysts
Date 16 April 2018 Theme Company Update Company Oncosil Medical (OSL) BUY: Cash and clinical data behind them now We are re-initiating coverage of Oncosil Medical with a BUY rating, following a Research
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationOncosil Medical (OSL) BUY: OncoPac-1 trial progress and validation. Key points. Risks and catalysts
Date 09 August 2017 Theme Company Update Company Oncosil Medical (OSL) BUY: OncoPac-1 trial progress and validation We maintain our BUY rating on Oncosil Medical with a 12-month price target of $0.38 per
More informationAdvancing Pancreatic & Liver Cancer Treatment
ASX.OSL Advancing Pancreatic & Liver Cancer Treatment Australian Biotech Invest 2017 October 24 th Melbourne 1 Important notice This Presentation has been prepared by Ltd (ASX:OSL) (OncoSil or the Company)
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationOncosil Medical (OSL) BUY: The CT-scans indicate good progress. Key points. Risks and catalysts
Date 24 October 2017 Theme Company Update Company Oncosil Medical (OSL) BUY: The CT-scans indicate good progress We maintain our BUY rating on Oncosil Medical and are sticking with our 12-month price target
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationFor personal use only
Sirtex Medical Limited SARAH Clinical Study Results Investor Presentation Nigel Lange, Interim CEO Dr David N. Cade, CMO 24 April 2017 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationOncosil (OSL) 100% Disease Control Rate. Maintain Buy (Speculative) Rating SOURCE: BELL POTTER SECURITIES ESTIMATES
Analyst John Hester 612 8224 2871 Oncosil (OSL) 23 October 2017 Speculative See key risks on Page 3 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationGlobal Invisible Braces Market: Trends, Opportunities and Forecasts ( )
Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationWorld leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationSmall-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK
Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationTransforming IVF and Biological Separations Presentation by Executive Chairman, Alison Coutts
Transforming IVF and Biological Separations Presentation by Executive Chairman, Alison Coutts NuSep (ASX:NSP) key facts No. shares 237,606,002 Market Cap. $7.1 million (@3 cps) No. of shareholders Approx.
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationInvestor Relations 1Q 2017
Investor Relations 1Q 2017 History Leading Authentic Sports Brand Inspired by the Style, Elegance and Passion of our Italian Heritage Founded by FILA brothers in Biella, Italy Established FILA Korea FILA
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More information22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationGlobal Prefilled Syringes Market: Trends, Opportunities and Forecasts ( )
Global Prefilled Syringes Market: Trends, Opportunities and Forecasts (2016-2021) By Material - Glass and Plastic By Filling Capabilities Single Chamber and Dual/Multiple Chamber By Major Applications
More information22nd Century Group, Inc. (XXII - $ Buy)
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationMDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationFor personal use only
MACQUARIE AUSTRALIA CONFERENCE 7 MAY 2015 JAMES THIEDEMAN GROUP CEO & MANAGING DIRECTOR DISCLAIMER The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ( MVF ) (including its
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationOrexigen Therapeutics, Inc.
February 27, 2015 Orexigen Therapeutics, Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 06/06/2012 Current Price (02/26/15) $5.87 Target Price $6.25 SUMMARY DATA
More informationCochlear Limited Results for the half year ended 31 December 2007
Cochlear Limited Results for the half year ended 31 December 2007 Chris Roberts Chief Executive Officer Neville Mitchell Chief Financial Officer Cochlear Overview Medical device company (~26yr): global
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationGlobal Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022
Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 By Value (In Million USD) By Volume (In Million Units)
More informationViralytics Limited (OTCQX: VRACY) VLA.AX - AUD ASX Buy
Joseph Pantginis, Ph.D., (646) 358-1907 jpantginis@roth.com Assaf Vestin, Ph.D., (646) 616-2785 avestin@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH April 14, 2015
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationM e d i a s e t G r o u p
M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%
More informationMDxHealth. Acceleration of payor coverage ConfirmMDx. Research Note.
Research Note MDxHealth Acceleration of payor coverage ConfirmMDx Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More informationBionor Pharma. Budding biomarker. A Vacc-4x biomarker to potentially drive success. Three clinical data readouts in next 12 months
Bionor Pharma Budding biomarker Q413 and pipeline update Pharma & biotech The discovery of a potential biomarker that could predict responders to Vacc-4x could help pave the way towards a potential functional
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationNOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX
Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,
More informationFor personal use only
Fisher & Paykel Healthcare Inspired and world-leading healthcare solutions FY2016 HALF YEAR RESULTS PRESENTATION 6 months ended 30 September 2015 1 First Half Result Highlights H1 FY2016 (6 months to 30
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationMDxHealth. AssureMDx leaves competition behind. Research Note.
Research Note MDxHealth AssureMDx leaves competition behind Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date:
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More information1Q 2009 Results Presentation. 12 May 2009
1Q 2009 Results Presentation 12 May 2009 1 Broadcasting 2 MEDIASET 2009 1Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs. 2008 +5.3% 15-64 years +5.6% 1Q TV CONSUMPTION (2000-2009) Average
More information2014 Full Year Results Presentation. Year ended 31 March 2014
2014 Full Year Results Presentation Year ended 31 March 2014 26-30 May 2014 1 Full year result highlights 12 months to 31 March 2014 NZ$M PCP CC 1 Record net profit after tax 97.1 +26% +46% Record operating
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationIN-DEPTH RESEARCH NOTE: The Hydroponics Company
IN-DEPTH RESEARCH NOTE: The Hydroponics Company Price: A$0.34 Price Target: A$0.48 ASX: THC 16 May 2017 THC has successfully raised funds through an IPO, which sets the Company up to deliver on its short
More informationPRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
More information(LO-NYSE) SUMMARY. Risk Level *
February 12, 2015 Lorillard Inc. (LO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 05/22/2012 Current Price (02/11/15) $67.55 Target Price $71.00
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES
Small-Cap Research February 24, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Update on
More informationMedivation, Inc. (MDVN-NASDAQ)
March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY
More informationInvestor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
More informationBlood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595
Transparency Market Research Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More information